Product Details
Product Name:
KKII5 |
CAS No.:
6381-55-1 |
Purity:
97.44% |
Supply Ability:
10g |
Release date:
2024/11/19 |
Product Introduction
Bioactivity
Name | KKII5 |
Description | KKII5 is a potent inhibitor of the lipoxygenase LOX-1 with an IC50 of 19 μM.KKII5 inhibits lipid peroxidation and enhances the ability of the active centers of some compounds to receive electrons. |
In vitro | KKII5 (100 μM) has a significant inhibitory effect on lipid peroxidation, with an inhibition rate of 98%.[1]
KKII5 interacts with HIS499 of the cavity by forming a π-π stacking interaction between the benzene ring of the molecule and the imidazole ring of HIS499.[1] |
Storage | Shipping with blue ice. |
Solubility Information | DMSO : 55 mg/mL (206.49 mM), Sonication is recommended.
|
Inhibitors Related | 2,5-Di-tert-butylhydroquinone | Caffeic Acid | 5-LOX inhibitor | Diethylcarbamazine citrate | Phenidone | Resveratrol | NNK | PF-4191834 | 5-Aminosalicylic Acid | Malotilate |
Related Compound Libraries | Bioactive Compound Library | Inhibitor Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
CAS:62473-79-4
$210.00 / 1mg
-
CAS:830-09-1
$98.00 / 10g
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$1.10/1g |
VIP4Y
|
Dideu Industries Group Limited
|
2021-12-17 |